KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortizatization of Intangibles: 2013-2024

Historic Amortizatization of Intangibles for Halozyme Therapeutics (HALO) over the last 11 years, with Dec 2024 value amounting to $71.0 million.

  • Halozyme Therapeutics' Amortizatization of Intangibles changed negligibly% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $71.0 million for FY2024, which is 3.69% down from last year.
  • Halozyme Therapeutics' Amortizatization of Intangibles amounted to $71.0 million in FY2024, which was down 3.69% from $73.8 million recorded in FY2023.
  • Halozyme Therapeutics' Amortizatization of Intangibles' 5-year high stood at $73.8 million during FY2023, with a 5-year trough of $3.6 million in FY2021.
  • Its 3-year average for Amortizatization of Intangibles is $62.7 million, with a median of $71.0 million in 2024.
  • As far as peak fluctuations go, Halozyme Therapeutics' Amortizatization of Intangibles tumbled by 74.24% in 2021, and later surged by 1,084.73% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Amortizatization of Intangibles (Yearly) stood at $14.1 million in 2020, then crashed by 74.24% to $3.6 million in 2021, then soared by 1,084.73% to $43.1 million in 2022, then soared by 70.98% to $73.8 million in 2023, then decreased by 3.69% to $71.0 million in 2024.